<DOC>
	<DOC>NCT00871104</DOC>
	<brief_summary>The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin, the standard therapy.</brief_summary>
	<brief_title>Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis</brief_title>
	<detailed_description />
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Endocarditis, Bacterial</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Suspected methicillinresistant staphyloccocus aureus infective endocarditis on a native valve, prosthetic valve or pacemakers´s electrode or defibrillators with definitive or probable diagnosis by the modified Duke criteria (Li J, et al. Clin Infect Dis. 2000). Patients over 18 years. Patients who did not sign informed consent. Patients with active consumption intravenous drug. Patients with emergent surgery criteria (&lt;72 hours). Patients or cardiogenic shock. Patients with antibiotic active against MRSA over 72 hours or they may need another antibiotic active against MRSA than those in the study. Patients with chronic renal failure on hemodialysis who received empirical treatment with vancomycin as a single dose and have a valley ≥ 15 mcg / mL on the third day. Patients with MRSA strains resistant to fosfomycin (MIC&gt; 64 mg / L) (&lt;10%) or vancomycin (MIC&gt; 2 mg / L) or with an MIC to vancomycin of 2 mg / L. Patients with any formal contraindication to be treated with study drugs Patients treated with any investigational drug within 30 days prior to entering the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Infective endocarditis</keyword>
</DOC>